The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Rockville, MD, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The global non-infectious macular edema treatment market is anticipated to secure a valuation of US$ 15,121.9 million in 2024. The global market is ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Compression socks help improve blood flow and reduce swelling in the feet and ankles. Here’s everything to know to decide if ...

Feb. 6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...